Application; Manufacturer of Controlled Substances

Federal Register: November 3, 2008 (Volume 73, Number 213)

Notices

Page 65404

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr03no08-74

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal

Regulations (CFR), this is notice that on July 15, 2008, Cedarburg

Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration

(DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug

Schedule

Tetrahydrocannabinols (7370)............... I

Dihydromorphine (9145)..................... I

Dihydrocodeine (9120)...................... II

Oxycodone (9143)........................... II

Hydromorphone (9150)....................... II

Hydrocodone (9193)......................... II

Remifentanil (9739)........................ II

Sufentanil (9740).......................... II

Fentanyl (9801)............................ II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of

Diversion Control, Federal Register Representative (ODL), 8701

Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 2, 2009.

Dated: October 28, 2008.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug

Enforcement Administration.

FR Doc. E8-26145 Filed 10-31-08; 8:45 am

BILLING CODE 4410-09-P

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT